








Referenze
1. Lymphoma Research Foundation. About lymphoma. [Internet; cited November 2018]. Available at: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6299689.
1. Cowan DH. Vera Peters and the curability of Hodgkin disease. Current Oncology. 2008; 15(5): 206-210.
2. Hodgkin T. On Some Morbid Appearances of the absorbent glands and spleen. 1832.
3. Lymphoma Research Foundation. About lymphoma. [Internet; cited November 2018]. Available at: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6299689.
4. Globocan 2018. World Fact Sheet. [Internet; cited November 2018]. Available at: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.]
5. American Society of Hematology. Lymphoma. [Internet; cited November 2018]. Available at: http://www.hematology.org/Patients/Cancers/Lymphoma.aspx.
6. Lyon, France: IARC Press; 2008. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues.
7. Shankland KR, Armitage JO, Hancock BW: Non-Hodgkin lymphoma. Lancet 380 (9844): 848-57, 2012
8. MedicineNet, Inc. (2011) Non-Hodgkin's Lymphoma: What are symptoms and signs of non-Hodgkin's lymphoma? [Internet; cited November 2018]. Available at: www.medicinenet.com/non-hodgkins_lymphomas/page4.htm.
9. National Institute for Health and Clinical Excellence Review of TA 110:rituximab for the first-line treatment of stage III-IV follicular lymphoma. [Internet; cited November 2018]. Available at: https://www.nice.org.uk/guidance/ta243/documents/follicular-lymphoma-rituximab-review-lymphoma-association2.
10. Lymphoma action. Diffuse large B-cell lymphoma. [Internet; cited November 2018]. Available at: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/diffuse-large-b-cell-lymphoma.
11. Maurer, JM et al. (2014). Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32: 1066-73.
Liu Q, et al. J Clin Oncol 24 (10): 1582-9, 2006